Drug Profile
Malaria DNA vaccine - Okairos AG
Alternative Names: AdCh63 ME-TRAP - Okairos AG; ChAd63 ME-TRAP - Okairos AG; ME-TRAP malaria DNA vaccine - Okairos AG/University of Oxford; MVA ME-TRAP - Okairos AGLatest Information Update: 16 Aug 2023
Price :
$50
*
At a glance
- Originator Okairos AG
- Developer Okairos AG; University of Oxford
- Class Antimalarials; DNA vaccines; Parasitic vaccines; Vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Malaria
Most Recent Events
- 06 Sep 2019 University of Oxford and Kenya Medical Research Institute plan a phase IIb trial for Falciparum malaria (Prevention, Combination therapy) in Kenya (IM, Injection), in January 2020 , (NCT03947190)
- 10 Sep 2018 Discontinued - Phase-II for Malaria (Prevention) in Senegal, United Kingdom, Kenya, Burkina Faso (IM)
- 09 Sep 2015 Phase-I/II development is ongoing in Burkina Faso